In January 2020, the U.S. Food and Drug Administration (FDA) approved the first and only therapy for treating thyroid eye disease. Teprotumumab, known by the brand name Tepezza, is a type of infusion therapy in which the treatment is delivered to the patient every three weeks for a total of eight infusions. Unfortunately, just over ...

The post ​What Hearing Complications Can Occur After Taking Tepezza? appeared first on Dolman Law Group.